← Back to Clinical Trials
Recruiting NCT06669962

NCT06669962 Characterisation of the Biochemical Profile and Physiology of the Coronary Circulation in Takotsubo Syndrome

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06669962
Status Recruiting
Phase
Sponsor A.O.U. Città della Salute e della Scienza
Condition Tako Tsubo Cardiomyopathy
Study Type OBSERVATIONAL
Enrollment 50 participants
Start Date 2024-07-10
Primary Completion 2026-06-27

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 90 Years
Study Type OBSERVATIONAL
Interventions
Study of coronary microcirculation and biomarkers of microvascular dysfunction

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 50 participants in total. It began in 2024-07-10 with a primary completion date of 2026-06-27.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Consecutive consenting patients over the age of 18 years diagnosed with Takotsubo syndrome according to the position statement of the European Journal of Heart Failure (2016) will be included in the study. The primary endpoint is to evaluate the incidence of coronary microcirculation dysfunction and its correlation with the clinical presentation and the prognosis in patients with TAKO-Tsubo syndrome. Secondary endpoints will be to assess the incidence of in-hospital mortality, the prevalence of cardiogenic shock, the correlation between the levels of biomarkers analyzed, microvascular dysfunction, perceived quality of life, and angina severity during hospitalization and at subsequent follow-ups, and the influence of knowledge of the level of microvascular dysfunction on clinical management and prescribed therapies. Enrolment: 2 years, follow-up: 1 month and 1 year. Total: 3 years.

Eligibility Criteria

Inclusion Criteria: * Age ≥ 18 years; * Diagnosis of Takotsubo syndrome * Signing of informed consent Exclusion Criteria: * Age \<18 years; * Refusal to sign written informed consent.

Contact & Investigator

Central Contact

Ovidio De Filippo, MD

✉ odefilippo@cittadellasalute.to.it

📞 +390116336023

Frequently Asked Questions

Who can join the NCT06669962 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Tako Tsubo Cardiomyopathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06669962 currently recruiting?

Yes, NCT06669962 is actively recruiting participants. Contact the research team at odefilippo@cittadellasalute.to.it for enrollment information.

Where is the NCT06669962 trial being conducted?

This trial is being conducted at Turin, Italy.

Who is sponsoring the NCT06669962 clinical trial?

NCT06669962 is sponsored by A.O.U. Città della Salute e della Scienza. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology